Bioprinting of Hybrid Tissue Engineering Constructs

Stanford Office of Technology Licensing, Palo Alto, CA, US

TECHNOLOGY SUMMARY

Stanford researchers have developed a 3D printing technology (“Hybprinter”) that can be used to form hybrid multi-material constructs incorporating a wide spectrum of materials (rigid and soft) and bioagents (such as cells and growth factors) with controlled spatial distribution across the hybrid structure. Due to its layer-by-layer manufacturing nature, Hybprinter enables the combination of cell-laden soft and hard biomaterials with a controlled spatial distribution for regenerative medicine applications. For instance, Hybprinter can be used to form connectable vascularized bone scaffolds composed of rigid, porous, osteoconductive load-bearing scaffolds and soft hydrogel vascular conduits (or channels containing soft hydrogel) with a high diffusion rate, thus eliminating the issues normally associated with surgical anastomosis of vascular grafts. The Hybprinting process also ensures high cell viability across the fabricated tissue engineering constructs.

AREA/MATURITY/AWARDS

Primary Application Area: Biotech, Pharma, Medical Devices

Technology Development Status: Prototype

Technology Readiness Level: TRL 4


SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

Innovation Awardee

Showcase Booth #: 522

Website: http://techfinder.stanford.edu/technology_detail.php?ID=31428


GOVT/EXTERNAL FUNDING SOURCES